CliffBio
biologic

Trogarzo

ibalizumab-uiyk

Loss of exclusivityMarch 2030projected — 12-year biologic exclusivity estimate
CompanyTheratechnologies →View the full company profile on CliffBio

Drug detail

Brand nameTrogarzo
Active ingredientibalizumab-uiyk
Strength200MG/1.33ML (150MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalMarch 2018
Marketing statusRx

More from Theratechnologies

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Trogarzo patent cliff — loss of exclusivity March 2030 | CliffBio